Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Jouary

Showing results (51-60 of 57) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 57 results.
British Journal of Cancer|May 4, 2016
First-in-human phase I study of the DNA-repair inhibitor DT01 in combination with radiotherapy in patients with skin metastases from melanomaC Le Tourneau, B Dreno, Y Kirova, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 14, 2011
Adjuvant prophylactic regional radiotherapy versus observation in stage I Merkel cell carcinoma: a multicentric prospective randomized studyT Jouary, C Leyral, B Dreno, et al.
The British Journal of Dermatology|August 7, 2012
Guidelines for the management of vitiligo: the European Dermatology Forum consensusA Taieb, A Alomar, M Böhm, et al.
Annales De Dermatologie Et De Venereologie|September 5, 2025
Impact of the COVID-19 pandemic on melanoma: A retrospective study from the French clinical database of melanoma patients (RIC-Mel)F Skowron, S Mouret, A Seigneurin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 6, 2017
Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 studyG V Long, K T Flaherty, D Stroyakovskiy, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 14, 2019
Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 studyG V Long, K T Flaherty, D Stroyakovskiy, et al.
Annales De Dermatologie Et De Venereologie|February 7, 2024
The combination of ipilimumab and nivolumab is still not reimbursed for BRAF-mutated melanoma patients in France: An unacceptable medical situation that raises ethical concernsM Amini-Adle, J-P Arnault, F Aubin, et al.
Pageof 6

Showing results (51-60 of 57) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 57 results.
British Journal of Cancer|May 4, 2016
First-in-human phase I study of the DNA-repair inhibitor DT01 in combination with radiotherapy in patients with skin metastases from melanomaC Le Tourneau, B Dreno, Y Kirova, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 14, 2011
Adjuvant prophylactic regional radiotherapy versus observation in stage I Merkel cell carcinoma: a multicentric prospective randomized studyT Jouary, C Leyral, B Dreno, et al.
The British Journal of Dermatology|August 7, 2012
Guidelines for the management of vitiligo: the European Dermatology Forum consensusA Taieb, A Alomar, M Böhm, et al.
Annales De Dermatologie Et De Venereologie|September 5, 2025
Impact of the COVID-19 pandemic on melanoma: A retrospective study from the French clinical database of melanoma patients (RIC-Mel)F Skowron, S Mouret, A Seigneurin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 6, 2017
Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 studyG V Long, K T Flaherty, D Stroyakovskiy, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 14, 2019
Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 studyG V Long, K T Flaherty, D Stroyakovskiy, et al.
Annales De Dermatologie Et De Venereologie|February 7, 2024
The combination of ipilimumab and nivolumab is still not reimbursed for BRAF-mutated melanoma patients in France: An unacceptable medical situation that raises ethical concernsM Amini-Adle, J-P Arnault, F Aubin, et al.
Pageof 6